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Survival has risen steadily since the 1970s for most cancers in adults in England and Wales, but persistent inequalities exist between
those living in affluent and deprived areas. These differences are not seen for children. For many of the common adult cancers, these
inequalities in survival (the ‘deprivation gap’) became more marked in the 1990s. This volume presents extended analyses of survival
for adults diagnosed during the 14 years 1986–1999 and followed up to 2001, including trends in overall survival in England and
Wales and trends in the deprivation gap in survival. The analyses include individual tumour data for 2.2 million cancer patients. This
article outlines the structure of the supplement – an article for each of the 20 most common cancers in adults, followed by an expert
commentary from one of the leading UK clinicians specialising in malignancies of that organ or system. The available data, quality
control and methods of analysis are described here, rather than repeated in each of the 20 articles. We open the discussion between
clinicians and epidemiologists on how to interpret the observed trends and inequalities in cancer survival, and we highlight some of
the most important contrasts in these very different points of view. Survival improved substantially for adult cancer patients in England
and Wales up to the end of the 20th century. Although socioeconomic inequalities in survival are remarkably persistent, the overall
patterns suggest that these inequalities are largely avoidable.
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The survival of cancer patients in England and Wales increased for
many of the common cancers during the 1970s and 1980s, but
there were persistent socioeconomic inequalities in survival for
most cancers in adults, even after correction for the higher
background risk of death in more deprived groups (Coleman et al,
1999). For most cancers, survival was lower for adults resident in
more deprived areas than for residents in more affluent areas – the
‘deprivation gap’ in survival. No such deprivation gap in survival
was observed for cancers in children.
The main aims of this study were to extend the cancer survival
trends for England and Wales to the end of the 20th century by
including adults diagnosed during the period 1986–1999 and
followed up to 2001, and to evaluate any changes in the
socioeconomic inequalities in survival. A summary has been
published (Coleman et al, 2004): briefly, it showed that survival
continued to increase for most of the 20 common types of cancer
in adults, but – again for most cancers – socioeconomic
inequalities in survival either remained unchanged, or actually
widened.
In this supplement, we present more extensive results on the
trends and socioeconomic inequalities in survival, with a separate
article on each of the 20 most common malignancies in adults.
Expert clinical commentary is provided on each set of results by
leading UK clinicians who specialise in the management of each
malignancy or group of malignancies. The aim was to set out in
detail the possible reasons (stage at presentation, impact of various
treatment modalities) for the observed changes in survival and the
deprivation gap. This unique pairing of epidemiology and expert
clinical analysis should provide a more complete picture of the
state of cancer survival and cancer care in England and Wales.
STRUCTURE OF THIS SUPPLEMENT
Data, methods and presentation of results are discussed here,
rather than in each of the 20 articles. We summarise cancer
registration in England and Wales, explain how the cancers were
defined, how a deprivation category was assigned to each patient
and how the life tables were constructed. We describe the range of
analytic approaches and the standard tables and graphics for the
results. *Correspondence: Dr B Rachet; E-mail: bernard.rachet@lshtm.ac.uk
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Each article contains a brief overview of the epidemiology
(frequency, age–sex incidence, causes, treatment and mortality)
of the cancer, including major shifts in diagnosis or treatment
during the 1990s. Major socioeconomic differences in trends in
incidence or mortality in England and Wales are noted. Changes in
the clinical or pathological definition of disease or in the intensity
of case finding are relevant for some cancers (e.g., prostate,
bladder and myeloma).
We present overall national trends in cancer patient survival up
to 10 years after diagnosis, adjusted for deprivation, for the periods
1986–1990, 1991–1995 and 1996–1999. Short-term predictions of
survival for patients diagnosed during 2000–2001 are presented.
Socioeconomic inequalities in survival in the same three calendar
periods are also presented, along with short-term predictions of
the deprivation gap in survival up to 10 years after diagnosis for
patients diagnosed during 2000–2001.
We offer a brief interpretation of these results from the
perspective of epidemiology and public health.
Clinical commentaries
Each article on population-based survival patterns for malignan-
cies of an organ or organ system is followed by a clinical
commentary. These two views of cancer patient survival are not
often presented together.
The commentaries cover the clinical presentation, diagnosis,
investigation and treatment of each cancer, and any changes since
the late 1980s, especially any progress in diagnostic investigation
or new treatment strategies that may have had an impact on
prognosis. The impact of the introduction of mass screening for
cancers of the cervix and breast in the late 1980s is discussed (mass
screening for bowel cancer did not start until 2006). The articles
also cover the introduction and dissemination of clinical guide-
lines for diagnosis and management.
The commentaries discuss the extent to which the trends and
socioeconomic inequalities in cancer survival could be explained
by socioeconomic differences in either individual factors or
healthcare system factors. These factors include the speed with
which patients seek healthcare, the efficiency of referral for
investigation, stage at diagnosis, access to specialist treatment or
care, compliance with treatment, comorbidity and nutritional or
immune status. Some commentaries discuss how insights from the
clinician’s practice in the treatment of individual patients can be
translated to the population level, and whether recent changes in
clinical practice may be expected to produce significant improve-
ments in survival at a population level over the next 5 to 10 years.
MATERIAL AND METHODS
This section provides a summary of cancer registration in England
and Wales, an explanation of how the cancers and deprivation
groups were defined, and a description of how the data were
prepared for analysis.
The cancer data comprise anonymised individual records for all
cancer patients diagnosed during 1986–1999 and registered by one
of the population-based cancer registries covering the whole of
England and Wales.
The cancer registration system
Cancer registries collect a small standard data set for all cancer
patients in a defined population. A regional cancer registration
system has covered the entire population of England and Wales
since 1962, and the National Cancer Registry has collated the
regional data to produce national information on cancer patterns
since then. The National Cancer Registry has been linked to the
National Health Service Central Register (NHSCR) since 1971.
NHSCR provides notification of the eventual death of all cancer
patients registered since 1 January 1971 whose record was
successfully ‘flagged’ at NHSCR with details of the initial cancer
registration. The National Cancer Registry also receives informa-
tion about the death of all people for whom cancer was mentioned
on the death certificate. In 1999, nine regional cancer registries
were operating in England, alongside the national cancer registry
for Wales. Data collection methods vary between cancer registries,
but the principal sources are hospital in-patient records and
pathology records.
Definition of cancer
Cancers were variously defined by their anatomic location (site),
their microscopic appearance (morphology) and whether their
behaviour was classified as benign, in situ or malignant. Only
malignant tumours were included. Solid tumours were generally
grouped for analysis on the basis of their anatomic location.
During 1986–1999, two coding systems for the site of tumours
were used by the National Cancer Registry: the ninth revision of
the International Classification of Diseases (ICD-9) for 1986–1994,
and ICD-10 for cases diagnosed in 1995 or later (World Health
Organisation, 1977, 1994). Coherent groups were constructed by
bridging the classifications.
Data extraction
Before extraction of the data for survival analysis, special efforts
were made to ensure that the National Cancer Registry was as up-
to-date as possible. Data sets that had been recently submitted by
regional registries were checked for late registrations of cancer
patients diagnosed up to 31 December 1999. The National Health
Service Central Register was checked to ensure that any deaths
occurring in cancer patients eligible for inclusion in the analysis
had been linked to the corresponding cancer registration. The data
were extracted from the National Cancer Registry on 5 November
2002, when the vital status (alive, emigrated, dead and not traced)
at 31 December 2001, the closing date for survival analyses, was
known for 98.4% of patients.
Data quality
Standard criteria were used to determine the eligibility of tumour
records for analysis. Records that did not meet basic criteria of
data quality, residence, tumour morphology and behaviour were
excluded. Thus of the 3 million registrations of a neoplasm in
adults in England and Wales during 1986–1999, some 11% were of
an in situ neoplasm, mainly of the cervix (Table 1). Exclusion of
these and other registrations considered ineligible left the records
for some 2.6 million adults (aged 15 years or more) registered with
one of the twenty types of malignant, invasive, primary neoplasm
for analysis.
Eligible tumour records were subjected to further exclusion
criteria, including age (15–99 years at diagnosis), unknown vital
status or sex, duplicate registration, multiple primary malignancy,
synchronous tumours, invalid dates or sequences of dates and
patients whose survival was zero or unknown. Ten per cent of
patients were excluded because their recorded survival time was
zero; these were mainly patients whose tumour registrations were
made from a death certificate only (DCO), and for whom the
duration of survival was therefore unknown. Other patients were
excluded because it was not their first primary cancer (3.2%) or for
other reasons such as unknown vital status (1.6%; Table 1). The
analyses included 2.2 million adults (84.1% of those eligible) who
were diagnosed with a first, primary, invasive malignancy during
1986–1999 and followed up to 31 December 2001.
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The observed probability of death among cancer patients has two
components: the probability of death from the cancer of interest
(the excess mortality) and the probability of death from all other
causes (the background mortality).
The probability of survival, the complement of mortality, can be
resolved into the same two components. The parameter of interest is
the survival from cancer in the absence of other causes of death, or
the ‘net probability of survival’ (Este `ve et al,1 9 9 4 ) .N e ts u r v i v a lc a n
be estimated in two ways. In cause-specific survival, only deaths
certified as due to the cancer of interest are considered as events in
the survival analysis, and deaths from other causes are censored,
along with persons lost to follow-up. This approach is not suitable for
population-based data, however, because information on the under-
lying cause of death, especially at long intervals of time after
diagnosis, is not sufficiently reliable to enable robust comparisons of
survival over time and place. Relative survival, the alternative
approach used here, is the ratio of the observed probability of
survival and the probability of survival that would have been expected
if the cancer patients had simply been subject to the background
mortality of the general population in which they live, given the same
initial distribution of prognostic factors such as age, sex, geographical
area, calendar period and socioeconomic factors (Berkson and Gage,
1950; Cutler and Ederer, 1958; Ederer et al, 1961).
Deprivation
The National Cancer Registry for England and Wales contains no
information about the income or socioeconomic status of
individual cancer patients. Instead, as with earlier analyses
(Dickman et al, 1998; Coleman et al, 1999) and more recent work
(Kaffashian et al, 2003; Shack et al, 2007), ecological measures of
deprivation were used, on the basis of characteristics of the small
area in which each patient was resident at the time of diagnosis.
The ranked national distribution of area deprivation scores was
divided into five equal categories by quintiles, and patients were
assigned a deprivation category from one (most affluent, or ‘rich’)
to five (most deprived, or ‘poor’), on the basis of their postcode of
residence at diagnosis. Two deprivation measures were used. For
patients diagnosed during 1986–1995, we used the Carstairs score
from the 1991 census, on the basis of car ownership, overcrowding,
unemployment and social class IV or V of the head of household
(Carstairs and Morris, 1989; Carstairs, 1995, 2000) in each electoral
ward, with an average of 2000 households. Data were not available
for all components of the Carstairs score after the 1991 census, and
the geographic distribution of deprivation changed substantially
during the 1990s, particularly for unemployment (Department for
Transport Local Government and the Regions (DTLR) and Social
Exclusion Unit, 2001). The most appropriate index of deprivation
for patients diagnosed during 1996–1999 was the income domain
score, a component of the Indices of Multiple Deprivation (IMD)
2000, derived separately for England (Department of the Environ-
ment Transport and the Regions, 2000) and Wales (National
Assembly for Wales, 2000). The electoral ward was the smallest
geographic area for which the IMD could be derived in England. In
Wales, it was the electoral division, an area of similar mean
population. The English and Welsh income domain scores are
closely equivalent, and the impact of categorising the deprivation
of cancer patients in Wales with the Welsh IMD instead of the
English IMD was judged minimal by the developers of both
indexes (Woods et al, 2005a).
In the Cancer Survival Trends monograph (Coleman et al, 1999),
the deprivation gap in survival for patients diagnosed up to 1990
was estimated using the census Enumeration District (ED) as the
geographic basis for assigning patients to a deprivation category.
EDs contain on average only 200 households, but electoral wards
(2000 households) were the smallest geographic unit for which the
IMD was available in later years. Therefore, in all the analyses
reported here, we used the electoral ward as the geographic unit.
We evaluated the impact of this change on the deprivation gap in
survival: for 29 of 34 sex-site combinations, the gap on the basis of
ward Carstairs scores was smaller than on the basis of ED Carstairs
scores (data not shown). The pattern for breast cancer is a typical
example (Figure 1) (Woods et al, 2005a).
Similarly, use of the income domain score instead of the
Carstairs score as the basis for determining the deprivation
category, both at ward level, led to virtually identical estimates of
the deprivation gap (data not shown). This implies that the
population of the geographic unit is more important than the
index of deprivation in measuring the deprivation gap in survival.
These changes in the index of deprivation and in the geographic
basis of its assignation to cancer patients mean that estimates of
the deprivation gap in survival in this supplement are not precisely
comparable with those published for patients diagnosed up to 1990
(Coleman et al, 1999). As expected, the dilution effect of using
larger geographic units in an ecological analysis tended to
attenuate the survival gradient slightly. The inclusion in these
analyses of patients diagnosed during 1986–1990, along with those
diagnosed during 1991–1999, nevertheless enables trends in the
deprivation gap in survival in the 15 years up to the end of the 20th
century to be evaluated on a consistent basis.
Abridged life tables
We constructed life tables centred on 1990–1992 and 1997–1999
for each sex and each deprivation category. For 1990–1992, the
denominators were 1991 census population counts by sex and
Table 1 Ineligible and excluded records, and number (% eligible) of
patients included in the analyses: adults (15–99 years) diagnosed with one
of twenty common malignancies, England and Wales, 1986–1999
No. %
Total registered 3018808
Ineligible
Incomplete data
a 6748 0.2
Patient not resident in England or Wales 14975 0.5
Tumour in situ (behaviour code 2) 322902 10.7
Tumour benign (behaviour code 0) or
uncertain if benign or malignant (1)
35427 1.2
Metastatic tumour (behaviour code 6 or 9) 9373 0.3
Otherwise ineligible
b 3909 0.1
393334 13.0
Total eligible 2625474 100.0
Exclusions from analysis
Aged 100 years or more at diagnosis 1009 o0.1
Vital status unknown at study closure date 42019 1.6
Sex not known 2 o0.1
Sex-site incompatibility 1253 o0.1
Invalid dates or invalid sequence of dates 3080 0.1
Zero survival or death certificate only (DCO) 272607 10.4
Duplicate registration
c 0 0.0
Synchronous tumours
d 12713 0.5
Multiple primary at the same site
e 5262 0.2
Multiple primary at a different site
e 79664 3.0
417609 15.9
Patients accepted for analyses 2207865 84.1
aMain data item(s) invalid or incompatible with one another: sex, date of birth, date of
diagnosis and (if present) date of death, postcode, site, morphology and behaviour.
bOther criteria of anatomic location, morphology or behaviour, specific to a particular
malignancy.
cSame site code, sex, cancer registry and cancer registry number as an
earlier registration.
dSame site code, sex, date of birth and date of diagnosis as
another registration(s): mostly synchronous or (in paired organs) bilateral tumours in
same anatomic site in one individual, not linked earlier: also some duplicate
registrations.
eSame site code and person number as an earlier registration(s): mostly
confirmed multiple primary tumours at the same or a different anatomic site, some
unresolved duplicate registrations.
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division in Wales. No such small-area denominators were available
for 1997–1999, and they were derived by applying Local Authority
age distributions from the 2001 census for England to the
populations of each ward in 1997 (Department of the Environment
Transport and the Regions, 2000; Office for National Statistics,
2003). Details have been published (Coleman et al, 2004). For
Wales, the counts of patients registered with general practitioners
by single year of age and sex were available for each electoral
division from the National Health Service Administrative Register.
The numbers of deaths registered in England and Wales by
5-year age group and sex were obtained from the Office for National
Statistics, for each small area and each year during 1990–1992 and
1997–1999. Only 0.35% of deaths in men and 0.2% in women could
not be attributed to a small area, and these were excluded.
The data on deaths and populations were aggregated across each
of the five deprivation categories for England and for Wales. The
annual average numbers of deaths by age, sex and deprivation
category during 1990–1992 and 1997–1999 were divided by the
corresponding populations for 1991 and 1998, to produce sets of
mortality rates (abridged life tables) by 5-year age group, sex and
deprivation, for each calendar period, both for each country and for
England and Wales combined. Construction of life tables centred on
a given year with the average annual number of deaths over a 3-year
period is standard actuarial practice, to obtain a more robust
estimate of deaths in age-sex groups with low mortality.
Complete life tables
The abridged life tables were smoothed, translated into complete
(single-year-of-age) mortality rates and extended up to 100 years
of age, using a reducible four-parameter model life table system
(Ewbank et al, 1983), constrained to three independent para-
meters, which modelled the overall level of mortality (the inter-
cept, a), the balance of mortality between young and old ages (the
slope, b), and the influence of the youngest ages on the overall
mortality (k) (Coleman et al, 1999). This approach reduced the
impact of minor inconsistencies in the population denominators
for 1998 (Woods et al, 2005b) and enabled mortality estimates to
be modelled for persons over 85 years of age, for whom no age-
specific details were available in the abridged data. The English
Life Table for 1991 by single year of age was used as the standard
against which other life tables were modelled (Government
Actuary’s Department, 2002). A comparison of the observed
(abridged) and smoothed (complete) mortality rates in 1998 for
males and females in the most affluent and most deprived
categories is shown in Figure 2.
National life tables by calendar period and sex were used to
examine overall cancer survival patterns. National life tables by
deprivation, period and sex were used to examine socioeconomic
differences in survival. Expected mortality for the period 1986–1995
was derived from the 1990–1992 life tables. The 1997–1999 life
tables were used for the period 1996–2001.
Relative survival
Relative survival directly reflects the excess mortality among the
cancer patients (Este `ve et al, 1990). All deaths during the study
period are included, and information on the cause of death is not
required. This is an advantage, especially with population-based
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Figure 1 Attenuation of the deprivation gradient in 1- and 5-year
survival (%) by the use of larger geographic units to assign the deprivation
category: Carstairs scores on the basis of census Enumeration Districts
(ED) and electoral wards, women diagnosed with breast cancer, England
and Wales, during 1991–1995. (Census Enumeration Districts have
populations of approximately 500 persons (200 households); electoral
wards have populations that are approximately ten times larger (see text).)
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as it corrects for the increasing background mortality with ageing
of the patient cohort. It is the only viable approach for the
comparison of cancer survival between population groups or
countries, as it also enables compensation for the wide interna-
tional differences in background mortality (Micheli et al, 2003a).
At each time (t) since diagnosis, the relative survival from the
cancer, Sr(t), is:
SrðtÞ¼SoðtÞ=SeðtÞð 1Þ
where So(t) and Se(t) are the observed and expected probabilities of
survival, respectively, each cumulated over all the successive
intervals within which survival is estimated, up to time t.
On the mortality scale, the observed mortality rate (lo) within a
given interval since diagnosis is equal to the sum of the
background mortality rate (le) and the excess mortality rate (lc),
which is considered as independent:
loðtÞ¼lcðtÞþleðx þ t;zÞð 2Þ
where x is the age of the patient at diagnosis. The background
mortality rate is the expected mortality rate for a person in the
general population at age (xþt), for the set (z) of factors such as
sex, country, year of death and deprivation category for which life
tables are available.
We used a relative survival model in which the excess mortality
hazard is estimated with a maximum likelihood approach from
individual tumour records (Este `ve et al, 1990). The baseline excess
hazard is estimated as a simple step function:
lcðtÞ¼
X m
k¼1
akIkðtÞð 3Þ
where ak is the excess mortality hazard in the kth interval since
diagnosis, and Ik(t) is an indicator, which is set to 1 in the kth
interval and 0 otherwise. This allows the excess mortality hazard to
change stepwise between the m prespecified intervals of time since
diagnosis, but to remain constant within each interval.
Interval structure
The assumption of a constant excess hazard of death from the
cancer may not be justified if time intervals are too wide,
particularly in the first few months after diagnosis. The lethality
of many cancers is highest then, before falling progressively, and
the interval structure must reflect this. In the first year after
diagnosis, therefore, we assessed survival probabilities within each
consecutive month up to 6 months, then 3-monthly intervals.
Estimates were made at 6-monthly intervals during 2 to 5 years,
then yearly up to 10 years. It may be impossible to estimate the
excess mortality if there are very few patients or very few deaths
within a given time interval, because the sparsity of data prevents
convergence of the maximum likelihood algorithm. In such cases
we reanalysed the data after progressive regrouping of the time
intervals, provided that estimates were available at exactly 1, 5 and
10 years after diagnosis.
Design of survival analyses
We estimated relative survival up to 10 years after diagnosis for
each cancer and sex, by calendar period of diagnosis and
deprivation category, using one of three designs: cohort, complete
and hybrid. Analyses were done with the programme strel, which is
in the public domain (Cancer Survival Group, 2006).
Follow-up ended on 31 December 2001, so all patients diagnosed
during 1986–1990 contributed to the estimate of survival up to 10
years after diagnosis (Figure 3). The probability of survival up to
10 years was estimated conventionally, as the cumulative product
of the probabilities of surviving each consecutive follow-up
interval from diagnosis up to 10 years. This corresponds to the
classical observation of a fixed cohort until all patients have been
followed up for at least the duration of survival being estimated.
For patients diagnosed during 1991–1995, the minimum
duration of follow-up was 6 years, but the number of patients
contributing to the estimate of survival is progressively smaller for
longer periods of follow-up. Thus, only patients diagnosed during
1991–1992 can provide an estimate of the probability of survival in
the tenth year after diagnosis (i.e., after at least 9 full years of follow-
up). All the follow-up data for patients diagnosed 1991–1995 can
still be used, however, in the ‘complete’ design (Figure 3).
For patients diagnosed during 1996–1999, the conditional
probability of survival in the fifth year after diagnosis was based
only on those diagnosed during 1996–1997. Ten-year survival
could not be estimated in cohort fashion, because none of the
patients had been followed up for 10 years. Longer-term survival
for patients diagnosed more recently can be predicted with the
period approach (Brenner and Gefeller, 1996), by using the most
recent period for which follow-up data are available for patients
who have in fact been followed up for 10 years. The principle is
identical to that used for ‘estimating’ life expectancy at birth. Death
rates from the most recent available year or period are used to
predict (rather than to estimate) the life expectancy of a baby born
in that year or period, on the assumption that she/he were subject
to the most recently observed risks of death at each age up to 80
years or more, that is, up to 80 or more years into the future. No
one expects last year’s death rates to remain fixed for 80 or more
years, so life expectancy at birth is a convenient summary of recent
mortality rates and, if death rates continue to decline, it will prove
     
Figure 3 Schema to show how the follow-up data contributed by cancer patients diagnosed in each year during 1986–1999 contribute to the survival
estimates for successive calendar periods using cohort, complete and hybrid approaches (see text).
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cohort, if we were to wait long enough to follow up its members to
measure their life expectancy directly.
The period approach to survival analysis adopts a parallel tactic
to provide short-term predictions of cancer survival. Follow-up
data are used from the most recent calendar period for which such
data are available up to, say, 10 years after diagnosis, to produce a
cumulative probability of survival up to 10 years. The follow-up
data do not relate to a fixed cohort of patients (Figure 3). A period
estimate of 10-year survival is a short-term prediction of survival
for patients diagnosed in that period, on the assumption that they
will experience the most recently observed conditional probabil-
ities of survival in each year up to 10 years since diagnosis. Because
survival is generally improving, a period estimate tends to be a
conservative estimate of the eventual 10-year survival of that
cohort of patients, when in due course we have observed their
follow-up for long enough to measure it directly.
A period estimate of survival from these data would have been
on the basis of the follow-up observed in the years 2000–2001 for
cancer patients diagnosed in the period 1990–1999, because no
incidence data were available for the last 2 years. In such a
situation, conventional period analysis leads to biased estimates of
survival and lack of statistical power. The optimal analytic
approach is a hybrid of the cohort and period approaches
(Brenner and Rachet, 2004), in which the most recent follow-up
data for up to 10 years are combined with follow-up data for the
first few years after diagnosis from the most recent cohort for
which such data are available (Figure 3, shaded area).
Survival trends, the deprivation gap in survival and
changes in the deprivation gap
Relative survival up to 10 years was estimated for patients in each
of five deprivation categories who were diagnosed in one of the
three calendar periods 1986–1990, 1991–1995 and 1996–1999.
This set of 15 survival estimates enabled three summary measures
to be derived for each cancer and in each sex: the average change
in survival over time, the average difference in survival between
the most deprived and most affluent groups (the ‘deprivation gap’
in survival), and the average change in the deprivation gap in
survival over time. The survival of patients diagnosed during
1986–1990 was used as the baseline for estimates of trend.
We used least-squares linear regression, weighted by the
variance of each of the relative survival estimates (Grizzle et al,
1969), in Stata software (StataCorp, 2006). The summary measures
were estimated by fitting a regression model to the survival
estimates with terms for calendar period and deprivation, then
adding a further term for interaction between period and
deprivation. The significance of the additional term was evaluated
with a likelihood ratio test at the 5% level.
The fitted average difference in survival between successive
calendar periods, adjusted for socioeconomic differences, is reported
in Table 1 of each cancer-specific article. For consistency with earlier
work, and because national estimates of survival rates do not
generally change very rapidly from year to year, we report the overall
national trends in relative survival as the absolute average change
every 5 calendar years, adjusted for change in the deprivation gap in
survival. Thus an increase from 50 to 55 and 60% in successive
5-year periods would be reported as a 5% increase every 5 years. The
same 5-yearly scale is used for trends in the deprivation gap,
weighted to take account of the shorter final period (4 years).
The absolute difference between the relative survival estimates
fitted by the regression model for the most affluent and most
deprived groups is described as the ‘deprivation gap’ in survival
(Figure 4). It is reported as negative if survival was lower for the
‘poorest’ patients than for the ‘richest’ patients. The linear models
generally fitted the data well, but the deprivation gap is not simply
the difference between survival in the richest and poorest groups:
it is a fitted estimate of the difference, incorporating the data for all
deprivation groups.
The deprivation gap in each of the three periods is shown in
Table 2 in each cancer article, together with the fitted change in the
deprivation gap over time. Both estimates are adjusted for time
trends in survival within each deprivation group.
Changes in the deprivation gap in survival between successive
calendar periods, adjusted for secular trends in survival, were
estimated from the interaction between calendar period and
deprivation. Thus the deprivation gap for rectal cancer widened
from  3.7% for women diagnosed during 1986–1990 to  8.3% for
women diagnosed during 1996–1999 (Figure 4), a weighted
average widening of  2.5% every 5 years.
These analyses were carried out separately for relative survival
at 1, 5 and 10 years after diagnosis, for 16 cancers in men and for
17 cancers in women.
DISCUSSION
The trends and inequalities in cancer survival in England and
Wales presented here for 1986–2001 extend the results for patients
diagnosed during the 20-year period 1971–1990 (Coleman et al,
1999). For most cancers, the additional analyses show that survival
up to 10 years after diagnosis increased for many of the 20 most
common cancers in adults, and suggest that the increases in
survival are likely to continue in the near future. Despite the
overall improvements, however, socioeconomic inequalities in
survival for many cancers among adults diagnosed up to 1990
widened further over the period 1986–2001 (Coleman et al, 2004).
The analyses reported here are more extensive than those
published in 2004. We present estimates and trends in survival up
to 10 years after diagnosis. We present the deprivation gap in
survival up to 10 years, and trends over time in this deprivation
gap at 1, 5 and 10 years after diagnosis. We used the recently
developed hybrid approach (Brenner and Rachet, 2004) to improve
short-term predictions of survival, because it is unbiased when, as
with the data available to us, the incidence data are not as recent as
the mortality data. It provides more precise estimates, with
narrower confidence intervals, because it includes additional
subjects who contribute to the conditional probabilities of relative
survival in the period immediately after diagnosis. In that setting,
the period approach is unstable. Thus the hybrid approach made it
possible, for the first time, to obtain robust short-term predictions
of socioeconomic differences in cancer survival up to 10 years after
diagnosis for patients diagnosed during 2000–2001.
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Figure 4 Schema to show how trends in the ‘deprivation gap’ in survival
are evaluated: 5-year relative survival, rectal cancer, women diagnosed
1986–1999, England and Wales.
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The patients seen by a given clinician are unlikely to be
representative of the entire population of cancer patients, but the
clinician has a great deal of information about the clinical and
personal picture when considering the management and likely
outcome for his or her patients.
Epidemiologists handle much more limited data on each patient,
but the data are available for virtually all cancer patients, without
selection, even patients who are not referred for specialist
treatment, and patients who are too sick when diagnosed to be
investigated with a view to treatment of curative intent.
These two perspectives of progress in cancer survival are often
in sharp but instructive contrast.
For example, the clinical commentary on trends in lung cancer
survival (Zee and Eisen, 2008) suggests that comorbidity can
influence the choice of surgery or adjuvant chemotherapy or
radiotherapy, so that if (or because) comorbidity is more marked
in the deprived socioeconomic groups, comorbidity could
indirectly influence the deprivation gap in survival. This clinical
observation merits further examination, not just for lung cancer
but also for cancers of other organs. One approach would be to use
data from the Hospital Episodes Statistics system.
Stage at diagnosis is also a contributory factor to these
differences in survival: tumour biology and factors related to the
healthcare system, such as access to treatment and medical
expertise, are also likely to contribute (Kogevinas, 1990; Kogevinas
et al, 1991; Kogevinas and Porta, 1997; Woods et al, 2006).
For most cancers, socioeconomic inequalities in relative survival
are no wider at 5 or 10 years after diagnosis than at 1 year,
suggesting that most of the difference in excess mortality between
rich and poor arises soon after diagnosis. This pattern roughly
mimics the pattern seen for elderly patients in England and Wales
(Coleman et al, 1999; Rachet et al, 2005). Elderly patients often
have much higher excess mortality than younger patients within
the first year or so after diagnosis, but the increased mortality in
the first year tends to be greatly attenuated, or to vanish altogether,
in the longer term.
Breast cancer is a striking exception to this pattern: deprived
women have lower survival than affluent women soon after the
diagnosis, but the socioeconomic inequalities in survival actually
widen with time since diagnosis, and the deprivation gap in
survival at 5 and 10 years is twice as wide as at 1 year after
diagnosis. Stage at diagnosis is unlikely to explain this pattern. The
most plausible explanation is socioeconomic differences in late
recurrence, which in turn could have several causes. Lower take-up
of radiotherapy has been shown to lead to higher recurrence (Early
Breast Cancer Trialists’ Collaborative Group, 2000) and lower
survival (Early Breast Cancer Trialists’ Collaborative Group,
2005b). Differences in access to chemotherapy or hormonal
therapy may also have contributed. Tamoxifen improves long-
term survival (Early Breast Cancer Trialists’ Collaborative Group,
2005a), and any socioeconomic differences in access to it in the
late 1990s could have had an impact on the survival gradient.
A different insight arises from ovarian cancer, for which survival
improved steadily over the period 1986–2001, continuing the trend
seen in earlier decades, whereas socioeconomic inequalities in
survival steadily declined over the same period. Thus 5-year relative
survival in England and Wales rose from 21 and 22% in the early and
late 1970s, respectively, to 27 and 28% in the early and late 1980s
(Coleman et al, 1999), up to 31 and 38% for women diagnosed in the
early and late 1990s (Cooper et al, 2008). For 1-year survival, the
deprivation gap remained at about  5%, but for 5-year survival,
the deprivation gap shrank in the early 1990s and had disappeared
by the late 1990s (þ1%). These trends evoked the comment
(Kitchener, 2008): ‘The deprivation gap at 1 year can probably be
explained by a greater proportion of women in deprived commu-
nities having advanced disease, and certainly in the past, poorer
access to optimal treatment. This would have resulted in a higher
proportion of treatment failures. Better access to specialist treatment
has seen this gap close’. He adds that the absence of a deprivation
gap in 5-year survival ‘probably also reflects improved access to
specialist treatment, and differences in comorbidity between richer
and poorer seem not to impact on survival.’
Interpretation
Most of the clinical commentators have interpreted the improve-
ments in survival over time as being directly attributable to
improvements in diagnosis and treatment (particularly surgery).
By contrast, they mostly attribute the socioeconomic inequalities
in survival to higher levels of comorbidity among the more
deprived patients. With some exceptions, socioeconomic inequal-
ities in prompt diagnosis and optimal treatment have not been
considered as a potential explanation for socioeconomic differ-
ences in survival.
This view is straightforward and inherently plausible, and it
derives directly from clinical experience, but it is challenged by
some of the results of this study.
Because relative survival estimates are compensated for
differences in background mortality among socioeconomic groups,
differential co-morbidity can only contribute to socioeconomic
differences in relative survival if there is an interaction between the
presence of comorbidity and the treatment actually received for
the cancer. Survival has been improving for both rich and poor
patients, but for many adult cancers, it has been improving more
rapidly for the rich than the poor, or at a similar speed for all
groups, that is, without closing the deprivation gap in survival.
If differential comorbidity between poor and rich cancer
patients were to explain those persistent or widening socio-
economic inequalities in survival, it would imply that the impact of
comorbidity on the choice (or the outcome) of treatment had
actually been increasing more among the poor than the rich. This
seems implausible.
Thus, for cancers of the colon and rectum, socioeconomic
differentials in 1-year and 5-year survival widened to 6–9% during
the 1990s, at the same time as overall survival for all socio-
economic groups combined improved by 10% or more over the
same period (Mitry et al, 2008). This is in marked contrast to the
pattern for ovarian cancer, for which the steady improvement in
survival was accompanied by a consistent narrowing of the
deprivation gap in survival. In the face of these patterns, it seems
difficult to sustain the view that greater comorbidity in the poor
than the rich can somehow underpin persistent socioeconomic
inequalities in survival.
Furthermore, the levels of survival among the most affluent
patients can in fact be attained by the most deprived. For many
cancers, as overall survival has improved, the poorest patients have
indeed attained the survival seen for the rich, but often only after a
time lag of some 5 years or so (see Figure 4). If the socioeconomic
differences in survival for patients diagnosed in a given period were
solely attributable to the impact of comorbidity on the choice (or the
outcome) of treatment, then the fact that survival in the poor ‘catches
up’ with survival in the rich, just a few years later, would imply that
the greater comorbidity in poorer cancer patients had somehow
vanished over the same period of time. This also seems unlikely, and
it is in direct contrast with the earlier argument.
Socioeconomic inequalities in diagnosis or treatment should be
seen as a potential alternative cause of differences in cancer
survival between social groups.
Racial differences in cancer survival in the United States
offer an instructive parallel. Blacks and the socioeconomically
disadvantaged are diagnosed at a later stage and have lower
survival (Mayberry et al, 1995; Bradley et al, 2002; Freeman and
Reuben, 2002; VanEenwyk et al, 2002), and racial disparities in
treatment, not explained by clinical factors, are associated with
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the equal-access healthcare system run by the Veterans Affairs
administration, however, there is very little racial difference in
survival among patients managed for colorectal cancer (Rabeneck
et al, 2003).
In Canada, with universal health insurance, the risk of death
within 30 days of hospital admission for stroke was inversely
associated with median neighbourhood income, and the excess
risk was still observable a year after admission. Patients in the
poorest fifth of neighbourhoods had less access to specialist
neurologists, and those who had carotid endarterectomy waited
much longer than patients in the richest neighbourhoods (Kapral
et al, 2002). This study is of nonmalignant disease, but it offers a
striking example of socioeconomic differences in treatment, care
and fatal outcome, in a universal-access healthcare system not
unlike that of the United Kingdom.
In the clinical setting, the natural interpretation of differences in
cancer survival turns on the adequacy of cancer management by a
clinical team or hospital, or in phase III randomised trials, on the
efficacy of a new treatment. Population-based cancer survival, by
contrast, is a much broader index of the overall performance of
healthcare systems (Micheli et al, 2003b), but it is often
misinterpreted simply as a direct reflection of the competence of
the physicians who treat cancer patients (Berrino and Capocaccia,
2008; Haward, 2008). The receipt of inadequate or suboptimal
treatment does not necessarily imply poor medical care. It may be
the result of differential availability of medical expertise, of policies
set by the healthcare providers, of the availability of healthcare
resources, or of differential compliance with treatment by the
patients themselves. We know, for example, that radiotherapy
waiting times have increased (Ash et al, 2004), but not whether the
impact is greater for patients living in deprived areas.
If we can accept that improvements in national levels of survival
are attributable to improved treatment – even in the absence of
hard evidence that the better treatments have in fact been made
available to all patients – then it seems coherent to accept that
differences in survival between subgroups of the population may
also be attributable, at least in part, to differences in access to those
improved treatments. Inequalities in access to treatment were a
key thrust behind the report of the Expert Advisory Group on
Cancer (Calman–Hine report) to the Chief Medical Officers of
England and Wales in 1995, in the middle of the period covered by
these analyses. The report recommended that: ‘all patients should
have access to a uniformly high standard of care in the community
or hospital, wherever they may live, to ensure the maximum
possible cure rates and best quality of life.’ (Expert Advisory Group
on Cancer, 1995).
SUMMARY
Cancer survival in England and Wales is generally improving, but
this supplement provides detailed evidence of persistent or
widening socioeconomic inequalities in survival for many of the
20 most common types of cancer during the last decade of the 20th
century, even after adjustment for socioeconomic differences in
background mortality.
These trends occurred during a period when equal access to
optimal diagnosis, treatment and care could scarcely have been
more prominent on the policy agenda (Expert Advisory Group on
Cancer, 1995; Department of Health, 2000, 2003; Cooper, 2001).
Randomised clinical trials provide the crucial evidence that new
approaches to the diagnosis or treatment of cancer are capable of
improving the outcome for cancer patients. That evidence is often
the bedrock for clinical guidelines as to how patients should be
investigated and treated. From the broader perspective of public
health and cancer control, it is equally important to monitor trends
in population-based survival, as an indicator of the extent to which
the potential for improved outcomes is actually translated into
better survival for all cancer patients.
We welcome the contribution of clinical specialists to explaining
both the trends and the persistent socioeconomic inequalities in
cancer survival. If this ‘confrontation’ of population-based cancer
survival data with expert clinical commentary were to become
routine, it might help advance our understanding of the causes of
socioeconomic inequalities in survival, and of what might be done
to reduce or avoid them. As one clinician recently put it: ‘We know
so much about socioeconomic inequalities in survival, yet we do so
little’ (Munro, 2005).
The cancer survival patterns reported here strongly suggest that
the socioeconomic inequalities in survival can indeed be reduced.
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